Table 1.
Dabigatran (n = 65) | Rivaroxaban (n = 34) | Apixaban (n = 14) | |
---|---|---|---|
Mean ± SD age, yr | 71 ± 11 | 70 ± 15 | 70 ± 14 |
Gender, n | |||
Male | 28 | 16 | 6 |
Female | 37 | 18 | 8 |
Indication, n | |||
Stroke prevention | 64 | 21 | 9 |
VTE prophylaxis/treatment | 1 | 13 | 5 |
Status of NOACs, n | |||
Home medication | 51 | 18 | 4 |
New start | 14 | 16 | 10 |
Cancer, n | 2 | 4 | 1 |
Concurrent use of antiplatelets, n | |||
Aspirin 325 mg | 3 | 0 | 0 |
Aspirin 81 mg | 18 | 9 | 4 |
Clopidogrel 75 mg | 1 | 1 | 1 |
VTE = venous thromboembolism, NOACs = novel oral anticoagulants.